PPIH — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

	Compound	Confidence	Supporting neighbours

Clinical trials — most relevant to PPIH by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia	PHASE3	COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs	PHASE1/PHASE2	RECRUITING
Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer.	PHASE1/PHASE2	COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Phase I/II Study of Heme Arginate and Tin Mesoporphyrin for Acute Porphyria	PHASE1/PHASE2	COMPLETED
Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn	PHASE1	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria	PHASE1	COMPLETED
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas	PHASE1	COMPLETED
Effectiveness of Physiologic Testing in PPI Non-Responders	EARLY_PHASE1	COMPLETED
Remote Ischemic Postconditioning Increases HIF-1α Plasma Levels and Improves Cardiac Markers After Cardiac Surgery	nan	COMPLETED
Prevalence and Intervention of Hypomagnesemia in Users of Proton-pump Inhibitors	nan	COMPLETED
Role of Circulating Pyrophosphate as a Biomarker of Mediacalcinosis in Type 2 Diabetic Patients	nan	RECRUITING
Long Term Prediction of MASH-related HCC Risk by Proteomics	nan	NOT_YET_RECRUITING
Biomarkers in the Etiology of Idiopathic Intracranial Hypertension	nan	UNKNOWN
Studies in Porphyria I: Characterization of Enzyme Defects	nan	UNKNOWN
Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing	nan	COMPLETED
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Portable Measurement of Protoporphyrin IX in the Skin	nan	COMPLETED
Biomarkers in the Diagnosis and Prognosis of NAFLD	nan	RECRUITING
Prevalence of Acute Hepatic Porphyria	nan	COMPLETED
Pulmonary Hypertension, Hypoxia and Sickle Cell Disease	nan	COMPLETED
Ovarian Reserve and Matrix Metalloproteinases	nan	COMPLETED
Efficacy of Low Dose Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding	nan	UNKNOWN
BMPR2 Mutations and Iron Metabolism in Pulmonary Arterial Hypertension	nan	COMPLETED
BJH-SDS Validation of the German Translation	nan	RECRUITING
Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC))	nan	COMPLETED
Treatment Response of Maintenance Dose of Proton Pump Inhibitor in Patients With Nonerosive Gatroesophageal Reflux Disease	nan	COMPLETED
Peripheral Perfusion Index in Acute Surgical Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PPIH binder may also engage these)

Protein	Name	Similarity
Q0P5D0	—	1.000	Q0P5D0 →
P52018	—	1.000	P52018 →
Q7SG06	—	0.999	Q7SG06 →
P0CP82	—	0.999	P0CP82 →
P0CP83	—	0.999	P0CP83 →
Q4WCM6	—	0.999	Q4WCM6 →
Q2TZ33	—	0.997	Q2TZ33 →
Q9ZVJ4	—	0.997	Q9ZVJ4 →
P35627	—	0.997	P35627 →
Q4P6X6	—	0.996	Q4P6X6 →
P0C1I3	—	0.996	P0C1I3 →
Q5AQL0	—	0.996	Q5AQL0 →
O00060	—	0.996	O00060 →
P25719	—	0.994	P25719 →
Q38900	—	0.994	Q38900 →
Q4IPH4	—	0.994	Q4IPH4 →
Q38867	—	0.994	Q38867 →
P0C1I8	—	0.993	P0C1I8 →
Q54SM3	—	0.992	Q54SM3 →
P34887	—	0.992	P34887 →
O74729	—	0.992	O74729 →
Q26994	—	0.991	Q26994 →
P52009	—	0.991	P52009 →
Q8W171	—	0.991	Q8W171 →
Q9SP02	—	0.991	Q9SP02 →
P0C1I0	—	0.991	P0C1I0 →
P24368	—	0.991	P24368 →
Q8HXS3	—	0.991	Q8HXS3 →
P52015	—	0.991	P52015 →
Q8SRE1	—	0.990	Q8SRE1 →